Phase 1 trial of transforming growth factor beta 2 in chronic progressive MS.
Transforming growth factor (TGF)-beta2 is a pleiotropic cytokine associated with remissions in multiple sclerosis (MS) and amelioration of allergic encephalomyelitis. We assessed the safety of TGF-beta2 in an open-label trial of 11 patients with secondary progressive (SP) MS. Five patients had a reversible decline in the glomerular filtration rate. There was no change in expanded disability status scale or MRI lesions during treatment. Systemic TGF-beta2 may be associated with reversible nephrotoxicity, and further investigation of its therapeutic potential in MS should be performed with caution.
Neuroimmunology Branch of the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892-1400, USA.
P A
PA
Calabresi
N S
NS
Fields
H W
HW
Maloni
A
A
Hanham
J
J
Carlino
J
J
Moore
M C
MC
Levin
S
S
Dhib-Jalbut
L R
LR
Tranquill
H
H
Austin
H F
HF
McFarland
M K
MK
Racke
D000328:Adult; D001806:Blood Urea Nitrogen; D002555:Cerebrospinal Fluid / Q000166:cytology; D002908:Chronic Disease; D005260:Female; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy*; D012079:Renal Circulation / Q000187:drug effects; D016212:Transforming Growth Factor beta / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000633:toxicity*
D016212:Transforming Growth Factor beta